Ezetyle P 2 Tablet contains Pitavastatin 2 mg and Ezetimibe 10 mg, a dual-action lipid-lowering combination formulated to help manage elevated cholesterol levels and support cardiovascular health. The medicine combines two complementary mechanisms that work together to reduce cholesterol production and absorption, providing comprehensive lipid control. It is prescribed under medical supervision as part of a broader strategy that may include dietary modifications, exercise, and lifestyle management.
Pitavastatin belongs to the statin class of medicines and works by inhibiting HMG-CoA reductase, an enzyme involved in cholesterol synthesis within the liver. Ezetimibe acts by reducing the absorption of cholesterol from the intestine, thereby lowering the amount of cholesterol entering the bloodstream. Together, these ingredients help reduce total cholesterol, low-density lipoprotein (LDL) cholesterol, and other lipid parameters associated with cardiovascular risk.
The tablet is commonly prescribed for hypercholesterolemia, mixed dyslipidemia, elevated LDL cholesterol, and other lipid disorders as advised by a healthcare professional. Regular use as part of a comprehensive cardiovascular risk management program may help improve lipid profiles and support long-term heart health. Treatment should be individualized according to the patient's clinical condition, cardiovascular risk factors, and treatment goals.
With the increasing prevalence of cardiovascular diseases, obesity, diabetes, and lifestyle-related lipid disorders, Ezetyle P 2 Tablet maintains strong demand in the cardiovascular segment. Its clinically established combination, physician acceptance, and importance in lipid management contribute to sustained market potential. The product offers valuable business opportunities and long-term growth prospects for retailers and distributors operating within the cardiovascular pharmaceutical sector.